Polymicrobial bloodstream infection in pediatric patients: risk factors, microbiology, and antimicrobial management

Deena Sutter1, David Stagliano, LoRanee Braun

  • 1Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. dsutter@usuhs.mil

Insights

Polymicrobial bloodstream infections (PBSIs) in children are linked to chronic medical conditions and may be more severe. Empiric antimicrobial therapy is often inadequate for these complex infections.

Area of Science:

  • Pediatric Infectious Diseases
  • Microbiology
  • Critical Care Medicine

Background:

  • Polymicrobial bloodstream infections (PBSIs) in children are understudied.
  • Previous reports suggest associations with underlying conditions and specific pathogens, but lacked control groups.
  • This study investigated risk factors, severity, and treatment adequacy for pediatric PBSIs.

Purpose of the Study:

  • To identify clinical risk factors associated with an increased risk of pediatric PBSIs.
  • To evaluate the clinical severity of PBSIs compared to monomicrobial infections.
  • To assess the adequacy of routine empiric antimicrobial therapy for PBSIs.

Main Methods:

  • Retrospective review of positive blood cultures from 1998 to 2004.
  • Age-matched comparison of patients with polymicrobial bloodstream infections (PBSIs) to those with monomicrobial bloodstream infections.
  • Analysis of underlying medical conditions, isolated organisms, therapy, and clinical outcomes.

Main Results:

  • Twenty-nine PBSI episodes were identified in 18 pediatric subjects.
  • PBSI patients more frequently had chronic conditions, gastrointestinal pathology, central venous catheters, and parenteral nutrition.
  • Common pathogens included Enterococcus spp., coagulase-negative staphylococci, and Candida spp.
  • Empiric antimicrobial therapy was less adequate for PBSIs.
  • PBSI patients experienced longer hospitalizations, intensive care unit stays, and prolonged bloodstream infections with higher sepsis severity.

Conclusions:

  • Chronic medical conditions, especially gastrointestinal disease, are significant risk factors for pediatric PBSIs.
  • Clinical illness in PBSI cases can be more severe.
  • Empiric antimicrobial regimens may require adjustment for high-risk pediatric patients.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...